In particular, genetic deletion and pharmacological inhibition of MMP-9 remarkably reduced microglial activation and dopaminergic neuronal degeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of PD [2,3]. This evidence concerns the gene MMP9 and Parkinson disease.